What is the recommended treatment for eczema?

Treatment of Eczema (Atopic Dermatitis)

For mild-to-moderate eczema, start with once-daily potent topical corticosteroids or tacrolimus 0.1% for sensitive areas, combined with regular emollients; for moderate-to-severe disease unresponsive to topicals, advance to JAK inhibitors (upadacitinib, abrocitinib), dupilumab, or cyclosporine as systemic therapy. 1, 2, 3

Topical Anti-Inflammatory Therapy (First-Line)

Potent Topical Corticosteroids

• Potent or very potent topical corticosteroids rank among the most effective treatments for both patient-reported symptoms and clinician-assessed signs, with moderate-to-high confidence evidence 2, 3
• Apply once daily, not twice daily—there is no additional benefit from twice-daily application 4
• Short-term use (median 3 weeks, up to 16 weeks) shows no evidence of increased skin thinning (low confidence), though longer-term use (6-60 months) carries a 0.3% risk of skin atrophy 2, 3
• Topical corticosteroids cause fewer application-site reactions compared to calcineurin inhibitors or PDE-4 inhibitors 2, 3

Topical Calcineurin Inhibitors

• Tacrolimus 0.1% ranks as highly effective as potent corticosteroids for symptom control and disease signs 2, 3
• Preferred for sensitive sites (face, eyelids, intertriginous areas) where corticosteroid side effects are concerning 1, 4
• Expect application-site reactions (burning, stinging) in approximately 2-3 times more patients than with corticosteroids, particularly with tacrolimus 0.1% (moderate confidence) 2, 3
• Pimecrolimus 1% is less effective than tacrolimus 0.1% and ranks among the least effective topical treatments 3

JAK Inhibitors (Topical)

• Ruxolitinib 1.5% and delgocitinib 0.5% rank among the most effective topical treatments, comparable to potent corticosteroids and tacrolimus 0.1% 2, 3
• Delgocitinib 0.25% also shows high effectiveness for investigator global assessment (moderate confidence) 3

PDE-4 Inhibitors

• Crisaborole 2% ranks among the least effective topical anti-inflammatory treatments across multiple efficacy measures 2, 3
• Causes high rates of application-site reactions (high confidence), second only to tacrolimus 0.1% 2, 3
• Difamilast and roflumilast similarly rank as less effective options 2, 3

Proactive Maintenance Therapy

• After achieving control, continue topical anti-inflammatory treatment 2-3 times weekly to previously affected areas to prevent flares ("get control then keep control" regimen) 5, 4

Systemic Therapy (Moderate-to-Severe Disease)

When to Advance to Systemic Therapy

• Consider systemic treatment when disease severity scores remain high despite optimized topical therapy, or when there is significant impact on quality of life 5
• Before initiating systemic therapy: optimize topical regimens, ensure adequate patient education, treat coexistent infections, rule out alternative diagnoses, avoid trigger factors, and consider phototherapy 5
• Do not rely on severity scores alone—assess both disease severity and quality-of-life impact holistically 5

First-Line Systemic Options

JAK Inhibitors (Oral)

• Upadacitinib 15-30 mg shows the highest real-world effectiveness, with 83% achieving EASI-75 and 55% achieving EASI-90 at 16 weeks 6
• Abrocitinib 100-200 mg achieves 75% EASI-75 and 38% EASI-90 at 16 weeks 6
• Baricitinib 2-4 mg achieves 51% EASI-75 and 24% EASI-90 at 16 weeks 6
• Monitor for acne (15-21% incidence) and herpes simplex virus reactivation (2-6% incidence), which are the most common reasons for discontinuation 6, 7
• Approved options include baricitinib, upadacitinib, and abrocitinib 1, 7

Biologics

• Dupilumab (IL-4/IL-13 inhibitor) is highly effective for moderate-to-severe AD 1, 7
• Tralokinumab (IL-13 inhibitor) and nemolizumab (IL-31 receptor inhibitor) are newer biologic options 7
• Biologics generally have favorable safety profiles compared to traditional immunosuppressants 1

Traditional Immunosuppressants

• Cyclosporine remains an option for severe refractory cases 5, 1, 7
• Methotrexate, azathioprine, and mycophenolate mofetil are alternative systemic immunosuppressants 5, 1
• These require more intensive monitoring than biologics or JAK inhibitors 5

Phototherapy

• UVA1 or narrowband UVB (311 nm) are preferred wavelengths for adjuvant therapy 8
• Consider phototherapy before advancing to systemic immunosuppressants in appropriate candidates 5, 1

Treatments to Avoid or Minimize

Oral Antihistamines

• There is little evidence supporting oral antihistamines for eczema treatment—they should not be routinely used 4

Antimicrobials

• Do not use oral or topical antistaphylococcal treatments for infected eczema unless there is clear clinical infection requiring treatment 4
• Antimicrobial treatment is justified only when microbial superinfection induces disease exacerbation 8

Probiotics

• Probiotics have not been shown to benefit eczema patients and should not be recommended 4

Systemic Corticosteroids

• Avoid systemic corticosteroids for long-term management due to adverse effects and rebound flares upon discontinuation 5, 1

Ineffective Adjunctive Treatments

• Silk clothing, ion-exchange water softeners, and emollient bath additives have not been shown to benefit eczema 4
• Emollients from birth do not prevent eczema and may increase risks of skin infections and food allergy 4

Essential Supportive Measures

Emollients and Barrier Care

• Regular emollient use is fundamental basic therapy for all severity levels 8
• Apply emollients liberally and frequently to maintain skin hydration 1, 8

Trigger Avoidance

• Identify and avoid specific provocation factors (irritants, allergens) 8
• Dietary restrictions should only be implemented for diagnosed individual food allergies—not empirically 8

Patient Education

• "Eczema school" educational programs have proven helpful for disease management 8
• Ensure adequate education on proper application techniques, treatment expectations, and trigger avoidance 5